BioAge Labs (BIOA) Other Non-Current Assets (2023 - 2026)
BioAge Labs' (BIOA) quarterly Other Non-Current Assets came in at $208000.0 in Q2 2026, down 12.24% year-over-year from $237000.0 in Q2 2025, and down 3.26% quarter-over-quarter from $215000.0 in Q1 2026.
Analysis
BioAge Labs (BIOA) Other Non-Current Assets (2023 - 2026) Analysis & Trends
BioAge Labs has disclosed Other Non-Current Assets across 4 years of filings, most recently posting $208000.0 for Q2 2026.
- In Q2 2026, Other Non-Current Assets fell 12.24% year-over-year to $208000.0; the TTM figure through Jun 2026 stood at $208000.0 (down 12.24% YoY), while the FY2025 annual figure was $216000.0, down 10.0% from the prior year.
- Other Non-Current Assets came in at $208000.0 for Q2 2026 at BioAge Labs, down from $215000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $3.3 million in Q4 2023 to a low of $208000.0 in Q2 2026.
- Average Other Non-Current Assets over 4 years is $610250.0, with a median of $232000.0 recorded in 2025.
- Year-over-year, Other Non-Current Assets sank 92.73% in 2024 and decreased 10.0% in 2025.
- Over 4 years, Other Non-Current Assets stood at $3.3 million in 2023, then slumped by 92.73% to $240000.0 in 2024, then slipped by 10.0% to $216000.0 in 2025, then slipped by 3.7% to $208000.0 in 2026.
- Per Business Quant data, the three most recent Other Non-Current Assets figures were $208000.0 in Q2 2026, $215000.0 in Q1 2026, and $216000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 12.98 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 4.75 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 2.31 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 124.00 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 618.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 831.80 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 104.44 Mn |
| 10 | BioAge Labs | 439.00 Mn | 439.00 Mn | -14.23 Mn | 208,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 208,000.00 |
| Mar 31, 2026 | 215,000.00 |
| Dec 31, 2025 | 216,000.00 |
| Sep 30, 2025 | 227,000.00 |
| Jun 30, 2025 | 237,000.00 |
| Mar 31, 2025 | 239,000.00 |
| Dec 31, 2024 | 240,000.00 |
| Dec 31, 2023 | 3.30 Mn |